Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Rare diseases 14

Rare Diseases

bleeding-disorders-therapeutics-market-size-share-trends-growth-forecast

Snippets - A Small piece of News or Article

Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?

Bleeding disorders, also known as coagulopathy, are a group of conditions in which the blood cannot clot properly due to the missing or defective protein. Bleeding Disorder can affect a person irrespective of his genders, ages and race and the person is likely to bleed more than the average person. A minor cut or scrape may result in intense bleeding. The coagulation factors are proteins in the blood that works with platelets and plays a vital role in the blood clot. Platelets, bound together to form the fibrin clot, and any defect in the clotting factors or platelets can lead to excessive or prolonged bleeding. Excessive bleeding during or after surgery and ...

Explore More...

Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates

Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

transthyretin amyloidosis

Calciphylaxis: Rare Yet Potentially Fatal

Gilead

Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO

Gilead

Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives

COMMERCIAL AND OTHERS

KEY CLINICAL OUTCOMES

FDA

Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

Notizia

Companion Diagnostics

Companion Diagnostics

Johnson & Johnson

Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune

Novo Nordisk

Snippet

Migraine

Snippet

transthyretin amyloidosis

Notizia

Johnson & Johnson

4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

Orphan drugs

Orphan Drug Act and Its Criticism

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly